
|Articles|April 1, 2003
- Psychiatric Times Vol 20 No 4
- Volume 20
- Issue 4
First Night On-Call, Coronary Care Unit
Poetry of the Times
Advertisement
I'm driving a knife-edge
mountain ridge at midnight,
no lines, no guard rails,
a semi screaming down my lane
ready to crush me with its cargo
of science I still need to learn.
A rusted out Chevy on my tail
scrapes an exhaust pipe and sends
sparks into darkness, their brief light
fading fast as facts I've memorized.
I don't know who will die tonight,
me or them, but I grip the wheel tight,
knuckles lit white by high-beams,
my own heart pounding, heading uphill,
engine moaning, pedal to the metal.
Articles in this issue
over 23 years ago
Global and Social Considerationsover 23 years ago
Security Alerts Trouble American Psycheover 23 years ago
Psychiatry's Hottest Niche Marketsover 23 years ago
The Last Frontier: Going Beyond the Limitsover 23 years ago
Secondary Traumatization in Mental Health Care Providersover 23 years ago
Changes in the Concept of PTSD and Traumaover 23 years ago
The DSM: Not Perfect, but Better Than the Alternativeover 23 years ago
Dump the DSM>!Advertisement
Related to this article

Learn how IPV shapes mental health from pregnancy to adulthood, and how clinicians assess risk, plan safety, and treat victims and perpetrators.

Early trial shows investigational orexin-2 agonist ALKS 7290 improves adult ADHD symptoms in 14 days, with tolerable safety, paving way for phase 2.

Open-label extension data show fasedienol appears well tolerated and steadily improves social anxiety scores with as-needed intranasal use, as Vistagen plans FDA discussions.

A case report and review of 13 similar cases suggest that late-onset clozapine neutropenia may sometimes reflect neutrophil margination rather than marrow suppression, with corticosteroids, granulocyte colony-stimulating factor, or lithium as possible, carefully monitored paths to continuing treatment.

Helus Pharma advances oral deuterated psilocin HLP003 for MDD, detailing new efficacy and safety analyses plus ongoing phase 3 PARADIGM trial updates.

Caplyta phase 3 data show rapid, significant mania symptom relief in bipolar I by day 3, sustained to week 3, with tolerable adverse effects.

Atypical psychedelics such as ketamine, MDMA, and ibogaine show fast-acting promise for depression, PTSD, and addiction beyond 5-HT2A.
Advertisement
Advertisement
Trending on Psychiatric Times
1
The Top 7 Atypical Psychedelics: A Brief Clinical Guide
2
Positive Topline Phase 3 Study Results: Lumateperone for Manic Episodes in Bipolar I Disorder
3
New Analyses of HLP003 for the Adjunctive Treatment of MDD
4
Positive Phase 1b Results Demonstrate Clinical Proof-of-Concept for ALKS 7290 in Adults With ADHD
5

